Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
The rising case numbers of the SARS-CoV-2 Omicron BA.4, BA.5, and BA.2.12.1 subvariants has generated serious concern about the course of the pandemic. Here we examine the neutralization resistance, infectivity, processing, and fusogenicity of spike from the BA.4/5 and BA.2.12.1 SARS-CoV-2 variants compared with other Omicron subvariants and Delta. Critically, we found that the new Omicron subvariants BA.4/5 and BA.2.12.1 were more resistant to neutralization by mRNA-vaccinated and boosted health care worker sera and Omicron-BA.1-wave patient sera than were the BA.1 and BA.2 variants. Interestingly, Delta-wave patient sera neutralized more efficiently against not only Delta but also BA.4/5 and BA.2.12.1 variants that also contain substitutions at position L452, similar to Delta. The BA.4/5 and BA.2.12.1 variants also exhibited higher fusogenicity, and increased spike processing, dependent on the L452 substitution. These results highlight the key role of the L452R and L452Q mutations in BA.4/5 and BA.2.12.1 subvariants.
Article activity feed
-
SciScore for 10.1101/2022.05.16.492158: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Demographic information was self-reported, and all subjects provided informed consent. Sex as a biological variable Sera were collected 3-4 weeks post-second vaccine dose for 15 HCWs (7 female and 8 male; median age 37; age range 31-56), which included 4 Moderna mRNA-1273 and 11 Pfizer/BioNTech BNT162b2 vaccinated HCWs. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Once dissociated, cells were fixed in 4% formaldehyde diluted in 1X PBS and stained with primary antibody anti-S1 (Sino Biological, 40150-T62). anti-S1suggested: NoneCells were then stained with secondary antibody … SciScore for 10.1101/2022.05.16.492158: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Demographic information was self-reported, and all subjects provided informed consent. Sex as a biological variable Sera were collected 3-4 weeks post-second vaccine dose for 15 HCWs (7 female and 8 male; median age 37; age range 31-56), which included 4 Moderna mRNA-1273 and 11 Pfizer/BioNTech BNT162b2 vaccinated HCWs. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Once dissociated, cells were fixed in 4% formaldehyde diluted in 1X PBS and stained with primary antibody anti-S1 (Sino Biological, 40150-T62). anti-S1suggested: NoneCells were then stained with secondary antibody anti-rabbit-IgG-FITC (Sigma, F9887) and processed by a Life Technologies Attune NxT flow cytometer. anti-rabbit-IgG-FITCsuggested: NoneMembranes were blotted with anti-S1 (Sino Biological, 40150-T62), anti-p24 (Abcam, ab63917; NIH ARP-1513), and anti-GAPDH (Santa Cruz Biotech, sc-47724). anti-GAPDHsuggested: (Santa Cruz Biotechnology Cat# sc-47724, RRID:AB_627678)Anti-mouse-IgG-Peroxidase (Sigma, A5278) and anti-rabbit-IgG-HRP (Sigma, A9169) were used as secondary antibodies accordingly. Anti-mouse-IgG-Peroxidasesuggested: Noneanti-rabbit-IgG-HRPsuggested: NoneExperimental Models: Cell Lines Sentences Resources HEK293T (ATCC CRL-11268, RRID: CVCL_1926) and HEK293T-ACE2 (BEI NR-52511, RRID: CVCL_A7UK) cells were maintained in DMEM (Gibco, 11965-092) supplemented with 10% FBS (Sigma, F1051) and 1% penicillin-streptomycin (HyClone, SV30010). HEK293Tdetected: (ATCC Cat# CRL-11268, RRID:CVCL_1926)HEK293T-ACE2detected: ( RRID:CVCL_A7UK)CaLu-3 cells (RRID: CVCL_0609) were maintained in EMEM (ATCC 30-2003) supplemented with 10% FBS and 1% penicillin-streptomycin. CaLu-3detected: (ATCC Cat# HTB-55, RRID:CVCL_0609)pNL4-3-inGluc and spike constructs were transfected into HEK-293T cells in a 2:1 ration using polyethylenimine transfection. HEK-293Tsuggested: NonePseudotyped virus for each SARS-CoV-2 spike, produced in parallel, were used to infect target HEK293T-ACE2 or CaLu-3 cells. CaLu-3suggested: KCLB Cat# 30055, RRID:CVCL_0609)Virus and serum were incubated for 1 hr at 37°C and then added to HEK293T-ACE2 cells for infection by neutralized virus. HEK293T-ACE2suggested: NoneSpike detection by flow cytometry: HEK293T cells used to produce pseudotyped vectors were harvested and fixed 72 hrs after transfection. HEK293Tsuggested: NoneRecombinant DNA Sentences Resources GenScript Biotech (Piscataway, NJ) produced and cloned SARS-CoV-2 spike constructs with N- and C-terminal flag tags using Kpn I and BamH I restriction enzyme cloning into a pcDNA3.1 vector. pcDNA3.1suggested: RRID:Addgene_79663)pNL4-3-inGluc and spike constructs were transfected into HEK-293T cells in a 2:1 ration using polyethylenimine transfection. pNL4-3-inGlucsuggested: NoneSoftware and Algorithms Sentences Resources NT50 values were determined by least-squares-fit, non-linear regression in GraphPad Prism 9 (San Diego, CA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results were analyzed using FlowJo v7.6.5 (Ashland, OR). FlowJosuggested: (FlowJo, RRID:SCR_008520)NT50 values were determined by least-squares fit non-linear regression in GraphPad Prism 9. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Western Blot quantification was performed using NIH ImageJ and by setting the ratio of S1/S and S1/p24 of BA.2 to 1.00. ImageJsuggested: (ImageJ, RRID:SCR_003070)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
